Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ZEGALOGUE (AUTOINJECTOR) vs CETRORELIX ACETATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Zegalogue (dasiglucagon) is a glucagon analog that binds to glucagon receptors, activating adenylate cyclase and increasing c AMP levels, which promotes glycogenolysis and gluconeogenesis in the liver, thereby raising blood glucose levels.
Gonadotropin-releasing hormone (Gn RH) antagonist. Competitively blocks Gn RH receptors on pituitary gonadotropes, inhibiting secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
Treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus aged 6 years and older,Off-label: Not specified
Inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology (ART)
0.25 mg intramuscularly (IM) as a single dose into the anterolateral thigh, repeated once after 15 minutes if necessary.
250 mcg subcutaneously once daily, starting on day 7 of ovarian stimulation and continuing until the day of h CG administration. Alternatively, a single 3 mg subcutaneous dose on day 7 of stimulation if h CG is given on day 9.
50–65 minutes (terminal elimination half-life).
Terminal elimination half-life: ~7-9 hours in healthy adults; prolonged to ~14-30 hours in patients with hepatic or renal impairment (clinical significance: no dose adjustment needed for mild-to-moderate renal or hepatic impairment, but caution in severe cases due to potential accumulation).
Primarily metabolized via proteolytic degradation into small peptides and amino acids; not metabolized by CYP450 enzymes.
Metabolized via peptidolysis; not significantly metabolized by cytochrome P450 enzymes.
Primarily hepatic metabolism followed by biliary and fecal excretion, with negligible renal elimination (<2%).
Primarily renal (excreted unchanged in urine ~42% within 24 hours; total urinary recovery ~66-69% over 8 days); biliary/fecal elimination accounts for <5%.
Negligible (<5%); not significantly bound to plasma proteins.
86-96% bound to albumin (alpha-1-acid glycoprotein binding not significant).
0.3–0.5 L/kg, indicating distribution primarily in extracellular fluid.
Apparent Vd: 1.14 L/kg (range 0.8–1.4 L/kg), indicating distribution primarily into extracellular fluid; not extensively tissue-bound.
100% after intramuscular injection (autoinjector).
Subcutaneous: ~85% (absolute bioavailability).
No dosage adjustment required for renal impairment.
No dose adjustment required for mild to moderate renal impairment (GFR ≥30 m L/min). Insufficient data for severe impairment (GFR <30 m L/min); use with caution.
No dosage adjustment required for hepatic impairment.
No dose adjustment recommended for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe impairment (Child-Pugh C); use with caution.
Weight-based dosing: 0.01 mg/kg IM (maximum 0.25 mg) into the anterolateral thigh, repeated once after 15 minutes if necessary.
Not indicated in pediatric patients (safety and efficacy not established).
No specific adjustment required; monitor for adverse effects due to potential comorbidities.
No specific dose adjustment; limited experience in women >65 years. Use with caution due to reduced renal and hepatic function.
None
None.
Risk of hypoglycemia due to overdose or inadequate response,Risk of nausea and vomiting,Risk of hypersensitivity reactions including anaphylaxis,Risk of hyperglycemia in patients with pheochromocytoma or insulinoma
Hypersensitivity reactions including anaphylaxis and urticaria.,Ovarian hyperstimulation syndrome (OHSS) due to gonadotropin therapy.,Pregnancy category X: contraindicated in pregnancy.,May cause fetal harm if administered during pregnancy.
Known hypersensitivity to dasiglucagon or any component of the formulation,Pheochromocytoma (risk of hypertensive crisis),Insulinoma (risk of hypoglycemia)
Hypersensitivity to cetrorelix acetate, mannitol, or any component.,Pregnancy and lactation.,Postmenopausal women.,Severe hepatic or renal impairment (safety not established).
No specific food interactions. However, after successful treatment, patients should consume fast-acting carbohydrates to stabilize blood glucose levels and prevent recurrent hypoglycemia.
No significant food interactions. No dietary restrictions required.
Zegalogue (dasiglucagon) is a glucagon analog; no adequate human studies exist. In animal reproduction studies, no evidence of fetal harm was observed at doses up to 600 times the MRHD. Risk cannot be ruled out; use only if clearly needed. First trimester: limited data; theoretical risk of hyperglycemia-related effects if maternal hypoglycemia not corrected. Second and third trimesters: same as first; no known teratogenicity.
Category X. Risk of congenital anomalies if pregnancy occurs. Avoid use during pregnancy; confirm negative pregnancy test before initiation. First trimester: No data; theoretical risk due to hormonal antagonism. Second and third trimesters: Not indicated for use; may interfere with pregnancy maintenance.
No data on dasiglucagon in human milk; excretion unknown. Glucagon is a peptide with low oral bioavailability; unlikely to be absorbed by infant. M/P ratio not available. Consider risk/benefit; monitor infant for hypoglycemia.
Not recommended during breastfeeding. M/P ratio unknown; cetrorelix is likely excreted in milk based on molecular weight; potential for adverse effects in the infant, including hormonal disruption.
No pharmacokinetic data in pregnancy; dose adjustment not recommended based on current evidence. Administer 0.6 mg as single subcutaneous dose regardless of gestational age. Monitor for recurrence of hypoglycemia; repeat dosing may be considered if needed.
Contraindicated in pregnancy; no dose adjustment recommended. Use only in non-pregnant patients. Pharmacokinetic changes in pregnancy unknown; drug not intended for use during gestation.
Zegalogue (dasiglucagon) is a glucagon analog indicated for severe hypoglycemia in diabetes patients aged 6 years and older. It is administered via autoinjector into the lower abdomen, outer thigh, or outer upper arm. Unlike reconstituted glucagon, it is stable in liquid form, allowing for rapid administration without reconstitution. Onset of action is within 10-15 minutes. Patients may experience nausea and vomiting; risk can be reduced by lying patient on side to prevent aspiration. Ensure patient has received carbohydrate intake once conscious to prevent recurrent hypoglycemia.
Administer subcutaneously in the lower abdominal wall. Rotate injection sites. Reconstitute with 1 m L of sterile water for injection or provided diluent; use immediately after reconstitution. Monitor for ovarian hyperstimulation syndrome (OHSS), especially in patients with polycystic ovary syndrome. Cetrorelix can cause transient injection site reactions. It is contraindicated in pregnancy and during lactation.
Use only for severe hypoglycemia where the patient is unable to take oral carbohydrates.,Inject into the lower abdomen, outer thigh, or outer upper arm through clothing if necessary.,Do not use if the solution is discolored or contains particles.,After injection, call emergency medical services immediately.,Turn patient on their side to prevent choking if vomiting occurs.,Once conscious, give fast-acting sugar (e.g., fruit juice, glucose tablets) to prevent recurrence.,Store at room temperature; do not freeze or expose to heat above 30°C (86°F).,Check expiration date before use.
Cetrorelix is used to prevent premature ovulation during fertility treatments.,Inject the medication exactly as prescribed, usually once daily in the abdomen.,Rotate injection sites and do not inject into irritated or bruised skin.,Do not skip doses; if a dose is missed, contact your healthcare provider.,Report any symptoms of OHSS such as severe pelvic pain, nausea, vomiting, or sudden weight gain.,This drug is not for use during pregnancy; inform your doctor if you think you are pregnant.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ZEGALOGUE (AUTOINJECTOR) vs CETRORELIX ACETATE, answered by our medical review team.
ZEGALOGUE (AUTOINJECTOR) is a GnRH Antagonist that works by Zegalogue (dasiglucagon) is a glucagon analog that binds to glucagon receptors, activating adenylate cyclase and increasing c AMP levels, which promotes glycogenolysis and gluconeogenesis in the liver, thereby raising blood glucose levels.. CETRORELIX ACETATE is a GnRH antagonist that works by Gonadotropin-releasing hormone (Gn RH) antagonist. Competitively blocks Gn RH receptors on pituitary gonadotropes, inhibiting secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ZEGALOGUE (AUTOINJECTOR) and CETRORELIX ACETATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ZEGALOGUE (AUTOINJECTOR) is: 0.25 mg intramuscularly (IM) as a single dose into the anterolateral thigh, repeated once after 15 minutes if necessary.. The standard adult dose of CETRORELIX ACETATE is: 250 mcg subcutaneously once daily, starting on day 7 of ovarian stimulation and continuing until the day of h CG administration. Alternatively, a single 3 mg subcutaneous dose on day 7 of stimulation if h CG is given on day 9.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ZEGALOGUE (AUTOINJECTOR) and CETRORELIX ACETATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ZEGALOGUE (AUTOINJECTOR) is classified as Category C. Zegalogue (dasiglucagon) is a glucagon analog; no adequate human studies exist. In animal reproduction studies, no evidence of fetal harm was observed at doses up to 600 times the . CETRORELIX ACETATE is classified as Category C. Category X. Risk of congenital anomalies if pregnancy occurs. Avoid use during pregnancy; confirm negative pregnancy test before initiation. First trimester: No data; theoretical r. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.